3BURAZERI G,CODA A,SULO G,et al.Conventional risk factors and acute coronary syndrome during a period of socioeconomic transition:population-based case-control study in Tirana,Albania[J].Croat Med J,2007,48 (2):225-233.
4FRANS V de W,JOEL M G,ALVARO A,et al.Access to catheterisation facilities in patients admitted with acute coronary syndrome:multinational registry study[J].BMJ,2005,330(7489):441.
5BRAUNWALDE,ANTMANEM,BEASLEYJW,et al.ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction:executive summary and recommendations[J].American Heart Association,2000,36 (3):970-1062.
6WILLIAMS S V,FIHN S D,GIBBOUS R T.Guidelines for management of plaques with chronic stable angina:diagnosis and risk strafication[J].Am Intern Med,2001,135 (7):530-547.
7MALARSTIG A,ERIKSSON P,HAMSTEN A,et al.Raised interleukin-10 is an indicator of poor outcome and enhanced systemic inflammation in patients with acute coronary syndrome[J].Heart,2008,94 (6):724-729.
8OSMAN R,L'ALLIER P L,N ELGHARIB,et al.Critical appraisal of e-reactive protein throughout the spectrum of cardiovascular disease[J].Vasc Health Risk Manag,2006,2(3):221-237.
9FRENCH J K,WHITE H D.Clinical implications of the new definition of myocardial infarction[J].Heart,2004,90 (1):99-106.
10CHENGSM,YANGSP,HO L J,et al.Irbesartan inhibits human T-lymphocyte activation through downregulation of activatorprotein-1[J].BrJ Pharmacol,2004,142 (6):933-942.
